Pharmaceutical

Rystiggo receives FDA approval, strengthening UCB’s myasthenia gravis portfolio

UCB's Rystiggo has been granted FDA approval to treat myasthenia gravis in anti-AchR or anti-MuSK antibody-positive adults.

Jun 27, 2023 - 20:00
Rystiggo receives FDA approval, strengthening UCB’s myasthenia gravis portfolio
UCB's Rystiggo has been granted FDA approval to treat myasthenia gravis in anti-AchR or anti-MuSK antibody-positive adults.
Read the original article

Tags:

Previous Article

Pfizer takes on haemophilia B gene therapy market with new FDA application

Next Article

Wane in Covid demand hurts Walgreens as profits drop to $118m

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: People with food insecurity deserve better nutrition education

Opinion: People with food insecurity deserve better nut...

Dec 27, 2023

STAT+: FDA advisory panel signals lack of confidence in data on Amgen’s cancer drug

STAT+: FDA advisory panel signals lack of confidence in...

Oct 6, 2023

Alvotech’s AVT05 in phase III rheumatoid arthritis study, as the sole candidate

Alvotech’s AVT05 in phase III rheumatoid arthritis stud...

Sep 23, 2023